ArticleRSC advances2024
New pyrazolo[3,4-
Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Synthesis, anti-proliferative evaluation, DFT,RSC advances · 2026Article
- Pyrimidine derivatives as anticancer agents targeting kinases: design strategies, biological evaluation, and structure-activity relationship insights.Molecular diversity · 2026Review
- Comparative bioactivities of Annona squamosa seeds and fruits: phytochemical insights and pharmacological evaluation.Scientific reports · 2026Article
- Synthesis of new pyrazolo[3,4-d]pyrimidines as potential mutant EGFR/HER2 and Bcl2 inhibitors: anticancer evaluation, DFT, molecular docking and ADME studies.BMC chemistry · 2026Article
- The utility of pyrimidine derivatives in the construction of azolo[RSC advances · 2026Review
- New benzochromene-based compounds as potential EGFR-TK inhibitors: synthesis, anti-proliferative activity, molecular docking studies, and ADME profiles.RSC advances · 2026Article
- A Comprehensive Review of Designing and Synthetic Aspects of Pyrazolopyrimidine Derivatives as Anticancer Agents.Mini reviews in medicinal chemistry · 2026Review
- Pyrazole and Pyrazoline-Based EGFR TK Inhibitors: A Review Study Emphasizing Structure-Activity Relationship (SAR).Medicinal chemistry (Shariqah (United Arab Emirates)) · 2026Review
- Design synthesis, characterization, molecular docking and antimicrobial evaluation of novel heterocycles with acrylonitrile and anthracene moieties.Scientific reports · 2025Article
- Gold nanoparticles synthesized from soil-derivedRSC advances · 2025Article
- Recent highlights in the synthesis and biological significance of pyrazole derivatives.Heliyon · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, four series of new pyrazolo[3,4-
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.